JP2003533490A - 抗腫瘍剤としてのアロマターゼ阻害剤および抗−ｈｅｒ２モノクローナル抗体 - Google Patents
抗腫瘍剤としてのアロマターゼ阻害剤および抗−ｈｅｒ２モノクローナル抗体Info
- Publication number
- JP2003533490A JP2003533490A JP2001583801A JP2001583801A JP2003533490A JP 2003533490 A JP2003533490 A JP 2003533490A JP 2001583801 A JP2001583801 A JP 2001583801A JP 2001583801 A JP2001583801 A JP 2001583801A JP 2003533490 A JP2003533490 A JP 2003533490A
- Authority
- JP
- Japan
- Prior art keywords
- her2
- aromatase inhibitor
- antibody
- exemestane
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003886 aromatase inhibitor Substances 0.000 title claims abstract description 39
- 229940046844 aromatase inhibitors Drugs 0.000 title description 11
- 239000002246 antineoplastic agent Substances 0.000 title description 2
- 229940122815 Aromatase inhibitor Drugs 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 25
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 23
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims abstract description 22
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims abstract description 22
- 230000001419 dependent effect Effects 0.000 claims abstract description 18
- 229940088597 hormone Drugs 0.000 claims abstract description 18
- 239000005556 hormone Substances 0.000 claims abstract description 18
- 238000012261 overproduction Methods 0.000 claims abstract description 14
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims abstract description 13
- 229960000255 exemestane Drugs 0.000 claims abstract description 13
- 230000000996 additive effect Effects 0.000 claims abstract description 12
- 230000002195 synergetic effect Effects 0.000 claims abstract description 11
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 11
- 239000000654 additive Substances 0.000 claims abstract description 10
- 229960002932 anastrozole Drugs 0.000 claims abstract description 9
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960000575 trastuzumab Drugs 0.000 claims abstract description 9
- 229960003881 letrozole Drugs 0.000 claims abstract description 6
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims abstract description 6
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229950011548 fadrozole Drugs 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 13
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 230000000259 anti-tumor effect Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 claims description 6
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 201000009273 Endometriosis Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 229960004421 formestane Drugs 0.000 claims description 4
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 3
- 229960003437 aminoglutethimide Drugs 0.000 claims description 3
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims description 3
- 229960004125 ketoconazole Drugs 0.000 claims description 3
- 150000002596 lactones Chemical class 0.000 claims description 3
- -1 logretimide Chemical compound 0.000 claims description 3
- 201000004228 ovarian endometrial cancer Diseases 0.000 claims description 3
- QXKJWHWUDVQATH-UHFFFAOYSA-N rogletimide Chemical compound C=1C=NC=CC=1C1(CC)CCC(=O)NC1=O QXKJWHWUDVQATH-UHFFFAOYSA-N 0.000 claims description 3
- 229960001670 trilostane Drugs 0.000 claims description 3
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 claims description 3
- 102000014654 Aromatase Human genes 0.000 claims description 2
- 108010078554 Aromatase Proteins 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229950004810 atamestane Drugs 0.000 claims 1
- 241000282412 Homo Species 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 2
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57135500A | 2000-05-15 | 2000-05-15 | |
| US09/571,355 | 2000-05-15 | ||
| PCT/EP2001/004468 WO2001087334A1 (en) | 2000-05-15 | 2001-04-19 | Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2003533490A true JP2003533490A (ja) | 2003-11-11 |
Family
ID=24283360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001583801A Withdrawn JP2003533490A (ja) | 2000-05-15 | 2001-04-19 | 抗腫瘍剤としてのアロマターゼ阻害剤および抗−ｈｅｒ２モノクローナル抗体 |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1282440A1 (es) |
| JP (1) | JP2003533490A (es) |
| KR (1) | KR20030014223A (es) |
| CN (1) | CN1429118A (es) |
| AU (1) | AU784617B2 (es) |
| BR (1) | BR0110732A (es) |
| CA (1) | CA2409652A1 (es) |
| CZ (1) | CZ20023748A3 (es) |
| EA (1) | EA005931B1 (es) |
| EE (1) | EE200200622A (es) |
| HK (1) | HK1054200A1 (es) |
| HU (1) | HUP0301877A2 (es) |
| IL (1) | IL152389A0 (es) |
| MX (1) | MXPA02011194A (es) |
| NO (1) | NO20025302L (es) |
| NZ (1) | NZ523004A (es) |
| PL (1) | PL360153A1 (es) |
| SK (1) | SK16022002A3 (es) |
| WO (1) | WO2001087334A1 (es) |
| ZA (1) | ZA200209815B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| KR20080038458A (ko) | 2000-05-19 | 2008-05-06 | 제넨테크, 인크. | ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인반응의 가능성을 개선시키기 위한 유전자 검출 분석 |
| EP1377298B1 (en) * | 2001-01-26 | 2006-08-30 | Pfizer Italia S.r.l. | Exemestane for treating hormono-dependent disorders |
| GB2375958B (en) | 2001-04-09 | 2005-03-02 | George Margetts | The use of steroids to lower the levels of cortisol |
| CN100424175C (zh) | 2002-03-26 | 2008-10-08 | 上海泽生科技开发有限公司 | ErbB-3 用于肿瘤治疗的方法和组合物 |
| JP2005534679A (ja) * | 2002-07-01 | 2005-11-17 | サビエント ファーマシューティカルズ，インコーポレイティド | 治療的処置のための組成物および方法 |
| FR2844455B1 (fr) * | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
| WO2006008639A1 (en) * | 2004-07-16 | 2006-01-26 | Pfizer Products Inc. | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
| PL1846030T3 (pl) | 2005-01-21 | 2019-05-31 | Genentech Inc | Ustalone dawkowanie przeciwciał her |
| EP3195879A1 (en) | 2005-02-23 | 2017-07-26 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients |
| WO2007045027A1 (en) * | 2005-10-19 | 2007-04-26 | Chavah Pty Ltd | Reduction of side effects from aromatase inhibitors used for treating breast cancer |
| WO2008109440A2 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her dimerisation inhibitor based on low her3 expression |
| EP2592156B1 (en) | 2007-06-08 | 2016-04-20 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| AR075896A1 (es) | 2009-03-20 | 2011-05-04 | Genentech Inc | Anticuerpos anti-her (factor de crecimiento epidermico) |
| WO2010136569A1 (en) | 2009-05-29 | 2010-12-02 | F. Hoffmann-La Roche Ag | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| CA2784211C (en) | 2010-02-18 | 2019-12-24 | Genentech, Inc. | Neuregulin antagonists and use thereof in treating cancer |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| WO2012069466A1 (en) | 2010-11-24 | 2012-05-31 | Novartis Ag | Multispecific molecules |
| SG191153A1 (en) | 2010-12-23 | 2013-07-31 | Hoffmann La Roche | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| CN102068429B (zh) * | 2010-12-28 | 2011-12-14 | 西南大学 | 法倔唑在诱导罗非鱼已分化卵巢转变为功能型精巢中的应用及其诱导方法 |
| CN103890007A (zh) | 2011-08-17 | 2014-06-25 | 霍夫曼-拉罗奇有限公司 | 神经调节蛋白抗体及其用途 |
| US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
| WO2013081645A2 (en) | 2011-11-30 | 2013-06-06 | Genentech, Inc. | Erbb3 mutations in cancer |
| EP2788500A1 (en) | 2011-12-09 | 2014-10-15 | F.Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
| JP2015514710A (ja) | 2012-03-27 | 2015-05-21 | ジェネンテック， インコーポレイテッド | Ｈｅｒ３阻害剤に関する診断及び治療 |
| US20160038490A1 (en) * | 2012-07-18 | 2016-02-11 | Angion Biomedica Corp. | Compositions and methods for treating dysproliferative diseases |
| CA2889298C (en) | 2012-11-30 | 2024-01-02 | Anton Belousov | Identification of patients in need of pd-l1 inhibitor cotherapy |
| WO2016061615A1 (en) | 2014-10-22 | 2016-04-28 | Chavah Pty Ltd | Methods of reducing mammographic breast density and/or breast cancer risk |
| EP3364978A4 (en) | 2015-10-22 | 2019-06-05 | Havah Therapeutics Pty Ltd | METHOD FOR REDUCING MAMMOGRAPHIC BREAST DENSITY AND / OR BREAST CANCER RISK |
| EP3454863A1 (en) | 2016-05-10 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
| CN107417791B (zh) * | 2017-08-17 | 2020-09-22 | 合肥瀚科迈博生物技术有限公司 | 抗人ErbB2双特异性抗体、其制备方法及用途 |
| JP2022535827A (ja) | 2019-06-03 | 2022-08-10 | ハバ セラピューティクス ピーティワイ エルティディ | アンドロゲン剤およびアロマターゼ阻害剤の送達のための医薬製剤およびシステム、ならびに使用のための方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
-
2001
- 2001-04-19 BR BR0110732-1A patent/BR0110732A/pt not_active IP Right Cessation
- 2001-04-19 SK SK1602-2002A patent/SK16022002A3/sk not_active Application Discontinuation
- 2001-04-19 KR KR1020027015223A patent/KR20030014223A/ko not_active Ceased
- 2001-04-19 IL IL15238901A patent/IL152389A0/xx unknown
- 2001-04-19 EE EEP200200622A patent/EE200200622A/xx unknown
- 2001-04-19 CN CN01809581A patent/CN1429118A/zh active Pending
- 2001-04-19 EP EP01929585A patent/EP1282440A1/en not_active Withdrawn
- 2001-04-19 EA EA200201213A patent/EA005931B1/ru not_active IP Right Cessation
- 2001-04-19 CA CA002409652A patent/CA2409652A1/en not_active Abandoned
- 2001-04-19 NZ NZ523004A patent/NZ523004A/en unknown
- 2001-04-19 PL PL36015301A patent/PL360153A1/xx not_active Application Discontinuation
- 2001-04-19 CZ CZ20023748A patent/CZ20023748A3/cs unknown
- 2001-04-19 JP JP2001583801A patent/JP2003533490A/ja not_active Withdrawn
- 2001-04-19 HU HU0301877A patent/HUP0301877A2/hu unknown
- 2001-04-19 WO PCT/EP2001/004468 patent/WO2001087334A1/en not_active Ceased
- 2001-04-19 AU AU56309/01A patent/AU784617B2/en not_active Ceased
- 2001-04-19 MX MXPA02011194A patent/MXPA02011194A/es not_active Application Discontinuation
- 2001-04-19 HK HK03106504.3A patent/HK1054200A1/zh unknown
-
2002
- 2002-11-05 NO NO20025302A patent/NO20025302L/no not_active Application Discontinuation
- 2002-12-03 ZA ZA200209815A patent/ZA200209815B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ523004A (en) | 2004-09-24 |
| EE200200622A (et) | 2004-06-15 |
| CA2409652A1 (en) | 2001-11-22 |
| EP1282440A1 (en) | 2003-02-12 |
| MXPA02011194A (es) | 2003-03-10 |
| KR20030014223A (ko) | 2003-02-15 |
| SK16022002A3 (sk) | 2003-04-01 |
| ZA200209815B (en) | 2003-12-03 |
| AU784617B2 (en) | 2006-05-18 |
| HK1054200A1 (zh) | 2003-11-21 |
| CZ20023748A3 (cs) | 2003-04-16 |
| CN1429118A (zh) | 2003-07-09 |
| AU5630901A (en) | 2001-11-26 |
| EA200201213A1 (ru) | 2003-04-24 |
| HUP0301877A2 (hu) | 2003-09-29 |
| PL360153A1 (en) | 2004-09-06 |
| BR0110732A (pt) | 2003-02-04 |
| EA005931B1 (ru) | 2005-08-25 |
| WO2001087334A1 (en) | 2001-11-22 |
| NO20025302D0 (no) | 2002-11-05 |
| NO20025302L (no) | 2002-11-05 |
| IL152389A0 (en) | 2003-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003533490A (ja) | 抗腫瘍剤としてのアロマターゼ阻害剤および抗−ｈｅｒ２モノクローナル抗体 | |
| US20050032759A1 (en) | Antitumor combined therapy | |
| CN102858335B (zh) | Erbb3抑制剂在三阴性乳腺癌和基底样乳腺癌治疗中的用途 | |
| AU2001239913B2 (en) | Method of treating cancer with anti-neurotrophin agents | |
| JP2023130496A (ja) | 癌治療のための併用療法 | |
| US20140134170A1 (en) | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers | |
| JP2003512298A (ja) | 癌治療のためのｒｈｕＭＡｂＨＥＲ２と組み合わせたドセタキセル | |
| JP2003504413A (ja) | 抗腫瘍物質を含む組み合わせ調製物 | |
| TW201536319A (zh) | 抗腫瘤劑及抗腫瘤效果增強劑 | |
| JP2003505432A (ja) | 抗ｅｐ−ｃａｍ抗体と化学療法剤との組合せ | |
| AU2024202832A1 (en) | Treatment of breast cancer using combination therapies comprising GDC-9545 and a CDK4/6 inhibitor | |
| JP2003527437A (ja) | 角化細胞増殖因子および上皮増殖因子阻害剤による組み合わせ処置 | |
| US20080008704A1 (en) | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies | |
| Tokuda et al. | Compassionate use of humanized anti-HER2/neu protein, trastuzumab for metastatic breast cancer in Japan | |
| CN115190800A (zh) | 一种brd4抑制剂的用途 | |
| Nozawa et al. | Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study | |
| EP3449939B1 (en) | Pharmaceutical composition for inhibiting metastasis of cancer, comprising, as active ingredient, antibody that specifically binds to epidermal growth factor receptor | |
| CA3210479A1 (en) | Treatment of breast cancer using combination therapies comprising gdc-9545 and abemaciclib or ribociclib | |
| JP2020125350A (ja) | 上皮成長因子受容体に特異的に結合する抗体を有効成分として含む、癌の転移を抑制するための医薬組成物 | |
| Dickler | ADVANCES IN ONCOLOGY | |
| NZ750260A (en) | Antitumor agent and antitumor effect enhancer | |
| NZ614427B2 (en) | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20071012 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20071012 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080416 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20090106 |